MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team

DURHAM, NC, and LIEGE, BELGIUM - August 18, 2011 - MDxHealth SA (NYSE Euronext:
MDXH), a leading molecular diagnostics company in the field of personalized
medicine, announced today that it has signed a lease agreement for a state-of-
the-art laboratory and office facilities in Irvine, CA and has filed for CLIA
certification of the US site. In addition, MDxHealth has filed for CLIA
certification of its Liege facility.
 
The  two-pronged  commercialization  strategy  of  the  company  is built on the
development of companion diagnostics with top tier pharmaceutical companies, and
on  developing its own proprietary  diagnostic, prognostic and predictive assays
for  a  number  of  cancer  indications  to  be  commercialized through its CLIA
laboratories. MDxHealth expects to launch its first assay for prostate cancer in
2012.
 
In  conjunction with identifying a prime  13,448 square foot location in Irvine,
MDxHealth  has hired Miriam Reyes, as Senior Director Laboratory Operations, and
Beth  Davis as Senior Director Managed  Care. Both bring extensive experience in
molecular  cancer diagnostics to MDxHealth. MDxHealth  is building a world class
scientific and commercial team for its US operations and plans further expansion
in  the  months  ahead.  In  September  2010, the  company already announced the
appointments of Dr. Melissa A. Thompson as Vice President Regulatory Affairs and
Quality  Assurance, and  of Christopher  Thibodeau as  Vice President Commercial
Operations.
 
"Establishing a US infrastructure that includes CLIA certification will allow us
to penetrate the US market more efficiently and is key to our long-term business
strategy,"  said Dr. Jan  Groen, CEO of  MDxHealth. "Irvine is  a hotbed for the
healthcare  industry and  an excellent  location for  our company to attract the
best  and brightest  talent, and  our site  is large  enough to  accommodate our
growth  over the next  few years. I  am also very  pleased that we  were able to
attract  two  highly  experienced  industry  professionals  to manage laboratory
operations and reimbursement."
 
About CLIA
In  the  US,  the  Centers  for  Medicare  &  Medicaid  Services (CMS) regulates
laboratory  testing  through  the  Clinical  Laboratory  Improvement  Amendments
(CLIA).  The  objective  of  the  CLIA  program  is to ensure quality laboratory
testing.  A CLIA lab  is a laboratory  that operates under  CLIA supervision. In
total,  CLIA covers approximately 200,000 laboratory entities. Unlike in Europe,
in  the US  almost 70% of  laboratory testing  is outsourced  to commercial CLIA
labs.  This constitutes a  highly attractive commercial  market, as one CLIA lab
can service the entire US.
 
About MDxHealth
MDxHealth   is  a  leading  molecular  diagnostics  company  that  develops  and
commercializes   oncology-based   molecular  diagnostic  testing  and  companion
diagnostics  for personalized medicine. The  company's numerous cancer tests are
based  on proprietary gene methylation technology and assist physicians with the
diagnosis of cancer, prognosis of recurrence risk, and prediction of response to
a  specific therapy. MDxHealth collaborates with leading cancer research centers
such  as Johns Hopkins University, Harvard Medical School, Beth Israel Deaconess
Medical  Center, Cleveland Clinic, Duke University, University of California Los
Angeles, Lovelace Respiratory Research Institute, University of Colorado Medical
Center, and major European academic medical centers. The company has a number of
commercial  and collaborative  partnerships with  LabCorp, Merck  & Co./Schering
Plough, GlaxoSmithKline Biologicals, Roche, Merck KGaA, Qiagen, Pfizer and other
industry leaders.
 
For more information:
 
 Dr. Jan Groen, CEO                    Hans Herklots
 
 MDxHealth                             Capricorn One
 
 +32 4 364 20 70                       +41 79 598 7149
 
This  press  release  contains  forward-looking  statements  and  estimates with
respect  to the  anticipated future  performance of  MDxHealth and the market in
which  it operates. Such  statements and estimates  are based on assumptions and
assessments  of known and unknown risks,  uncertainties and other factors, which
were  deemed  reasonable  but  may  not  prove  to be correct. Actual events are
difficult  to predict,  may depend  upon factors  that are  beyond the Company's
control,  and  may  turn  out  to  be  materially different. MDxHealth expressly
disclaims  any obligation to update any  such forward-looking statements in this
release  to reflect any  change in its  expectations with regard  thereto or any
change  in events,  conditions or  circumstances on  which any such statement is
based unless required by law or regulation
 
2011-08-18 ENG: 
http://hugin.info/137314/R/1538849/470298.pdf
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: MdxHealth via Thomson Reuters ONE
 
[HUG#1538849]